ADCETRIS (Takeda Pharmaceuticals Australia Pty Ltd)
Product name
ADCETRIS
Date registered
Evaluation commenced
Decision date
Approval time
146 working days (255)
Active ingredients
brentuximab vedotin
Registration type
EOI
Indication
Peripheral T-cell lymphoma
ADCETRIS (powder for injection) is now also indicated for the treatment of adult patients with previously untreated CD30+ peripheral T-cell lymphoma (PTCL) in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) (see 5.1 Pharmacodynamic Propertues, Clinical Trials).